Biosergen AB reported earnings results for the full year ended December 31, 2023. For the full year, the company reported revenue was SEK 9.38 million compared to SEK 5.18 million a year ago. Net loss was SEK 27.04 million compared to SEK 39.91 million a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.39 SEK | +2.90% |
|
+4.28% | -55.68% |
Jul. 12 | Biosergen AB Announces First Patient in Biosergen Clinical Trial Treating with Biosergen for Life Threatening Fungal Infection | CI |
Jun. 14 | Biosergen AB Approves Board Changes | CI |
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-55.68% | 5.27M | |
+20.12% | 126B | |
+25.25% | 119B | |
+25.56% | 27.95B | |
-19.51% | 20.5B | |
-14.36% | 17.12B | |
-15.63% | 16.1B | |
-46.67% | 14.97B | |
+11.89% | 14.84B | |
+57.74% | 14.38B |
- Stock Market
- Equities
- BIOSGN Stock
- News Biosergen AB
- Biosergen AB Reports Earnings Results for the Full Year Ended December 31, 2023